Insulin Injection Pen Market Research: Global Status & Forecast by Geography, Type & Application (2017-2027)

 

The market study on the global Insulin Injection Pen market will encompass the entire ecosystem of the industry, covering major regions namely North America, Europe, Asia Pacific, South America, Middle East & Africa, and the major countries falling under those regions. The study will feature estimates in terms of sales revenue and consumption from 2019 to 2026, at the global level and across the major regions mentioned above. The study has been created using a unique research methodology specifically designed for this market.

Quantitative information includes Insulin Injection Pen market estimates & forecast for a upcoming years, at the global level, split across the key segments covered under the scope of the study, and the major regions and countries. Sales revenue and consumption estimates, year-on-year growth analysis, price estimation and trend analysis, etc. will be a part of quantitative information for the mentioned segments and regions/countries.

Know more https://www.insidemarketreports.com/report/4/900012/Insulin-Injection-Pen

Insulin Injection Pen Market Major players

Novo Nordisk A/S
Eli Lilly and Company
AstraZeneca plc
Biocon Ltd.
Sanofi S.A.
Becton, Dickinson and Company
F. Hoffman-La Roche
Owen Mumford Ltd
Jiangsu Delfu Co., Ltd.

Insulin Injection Pen Market Segmentation

Based on Product Type Insulin Injection Pen Market is segmented into:

Reusable Pens
Disposable Pens

Based on Application Insulin Injection Pen Market is segmented into:

Hospital
Diabetes Clinics/ Centers
Home

Based on Region Insulin Injection Pen Market is segmented into:

North America
Europe

Asia-Pacific
South America
Middle East & Africa

Get sample report https://www.insidemarketreports.com/sample-request/4/900012/insulin-injection-pen-markets

Insulin Injection Pen Market Recent Updates

In 2020, The Brazilian National Health Surveillance Agency granted Gan & Lee's insulin glargine injection and insulin glargine injection (prefilled pen) registration certificates (ANVISA). Following that, the first shipments of these products were successfully delivered to Brazil in early 2021. In August 2020, The Mini Med 770G System, a hybrid closed-loop diabetes management device intended to automatically monitor glucose (sugar) and provide appropriate basal insulin doses with little or no input from users or caregivers, has been approved by the US and Drug Administration for use by individuals aged 2 to 6 with type 1 diabetes. In January 2020, BD (Becton, Dickinson, and Company), a leading global medical technology company, has received 510(k) clearance from the US and Drug Administration for its second-generation BD Nano pen needle, which is designed for more consistent subcutaneous injection depth.